

Rx Bandz Receives DOW Research Contract

Award Funds Battlefield Antibiotic Auto-Injector

DENVILLE, NJ, UNITED STATES, October 15, 2026 /EINPresswire.com/ -- [Rx Bandz](#), Inc, a medical device and drug formulation platform company, announced today it was awarded another research and development contract with the US Department of War

The SBIR Phase I contract provides Rx Bandz's cooperative work with the US military to fulfill the US military's preferences for antibiotics deliverable through the company's compact auto-injectors.

The company's platform of auto-injectors, which includes its ultra compact Miniject, can deliver from 1 mL to 5 mL of therapeutics from small-molecules to viscous biologics (including

“

The company's platform of auto-injectors, which includes its ultra compact Miniject, can deliver from 1 mL to 5 mL of therapeutics from small-molecules to viscous biologics (including hydrogels).”

Jessica Walsh

hydrogels). This versatility in drug delivery is unique to Rx Bandz's platform and is one of the reasons the DOW has contracted with the company to develop auto-injectors for ketamine and hydromorphone (for pain management), tranexamic acid (hemorrhage control) and epinephrine (shock).

The company is currently advancing two five-year \$23M contracts to its auto-injectors and developing its pipeline of drugs for the battlefield.

Jessica Walsh, Founder and CEO of Rx Bandz, said, “We are

honored that the Department of War continues to support our development of unique auto-injectors. There is a clear need for our rugged and versatile auto-injectors in both the military and for civilians, EMS, hospitals and clinics.”

Half of combat wounds sustained in austere or forward-deployed combat environments become



Rx Bandz has developed a novel drug delivery platform for emergency injectable drugs

infected. Delayed access to antibiotic treatment, due to combat conditions, environmental factors, or limited medical evacuation capabilities, significantly increases the risk of death from infection and imposes additional burden on field medical personnel.

Rx Bandz's devices will enable antibiotics to be delivered quickly at the point of injury or during evacuation, addressing infections at the earliest possible stage. This rapid-response treatment approach will dramatically reduce infection rates and survivability.

Rx Bandz is in the midst of its Series A equity funding round that will support the company's commercial efforts as it prepares to submit its Device Master File to the FDA by the end of the 2026 calendar year.

About Rx Bandz

Rx Bandz is a privately held, multi-asset biotechnology company developing a platform of patient-centric auto-injectors and proprietary drug formulations. Operating from its laboratory in Denville, New Jersey, the company is advancing the next generation of compact auto-injectors designed to improve the delivery of injectable medications for emergency medical conditions. Its auto-injector platform is being developed to deliver epinephrine (anaphylaxis), ketamine and hydromorphone (pain management), tranexamic acid (hemorrhages) and other emergency medications. Designed to be compact, easy to use, and rapidly deployable, Miniject® aims to improve patient access to life-saving emergency treatment. The company's platform also includes auto-injectors capable of delivering injectable therapies ranging from 1 mL to 5 mL across a range of medication viscosities.

For more information, visit www.RxBandz.com.

Myrna Walsh

Rx Bandz

+1 617-347-3475

Visit us on social media:

[LinkedIn](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/949127983>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2026 Newsmatics Inc. All Right Reserved.